menu search

Is ayr wellness inc. (ayrwf) outperforming other medical stocks this year?

Here is how Ayr Wellness Inc. (AYRWF) and biomea Fusion, Inc. (BMEA) have performed compared to their s...

October 5, 2023, 11:17 am

biomea fusion announces appointment of juan pablo frías, m.d. as chief medical officer

Industry veteran and prominent diabetes clinical development expert to oversee biomea’s progressing c...

August 31, 2023, 12:30 pm

biomea fusion: potential cure for diabetes, initiating with a buy

biomea Fusion is a clinical-stage biotech company developing covalent small molecule inhibitors, with i...

July 16, 2023, 1:39 am

Are (more) big gains ahead for this small cap biotech stock?

A year removed from its $20 IPO of April 2021, biomea Fusion, Inc. NASDAQ: BMEA faded into penny stock ...

June 28, 2023, 8:57 am

biomea fusion stock soars after release of clinical data on diabetes treatment

Shares of biomea Fusion Inc. BMEA, -5.89% jumped 17% in premarket trading Monday after the clinical-sta...

June 26, 2023, 8:17 am

biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

biomea fusion to present late breaking data from ongoing phase ii trial, covalent-111, evaluating bmf-219 in patients with type 2 diabetes at ada 2023

New clinical data from COVALENT-111 will be unveiled during a late-breaking poster presentation at ADA’s Scientific Sessions BMF-219, an orally deli...

June 20, 2023, 8:30 pm

biomea fusion to present late breaking data from ongoing phase ii trial, covalent-111, evaluating bmf-219 in patients with type 2 diabetes at ada 2023

REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- biomea Fusion, Inc. (“...

June 20, 2023, 4:30 pm

biomea: novel approach to diabetes and cancer

BMEA develops oral covalent small molecules for cancer and diabetes. Its lead asset is a menin inhibitor....

May 28, 2023, 7:57 am

Why biomea fusion stock crushed it this week

Tuesday, biomea Fusion announced encouraging mid-stage trial results for its type 2 diabetes candidate....

March 30, 2023, 2:35 pm

biomea (bmea) up 99% on upbeat data from type ii diabetes study

Preliminary data from an ongoing mid-stage study shows that treatment with biomea's (BMEA) lead candida...

March 29, 2023, 1:46 pm

Bmea stock: biomea fusion pops on public offering news

biomea Fusion (NASDAQ: BMEA ) stock is climbing higher on Wednesday after the company announced a publi...

March 29, 2023, 11:05 am

biomea fusion stock pulls back after $125 million stock offering follows record rally

Shares of biomea Fusion Inc. BMEA slumped 2.0% in premarket trading Wednesday, after the biopharmaceuti...

March 29, 2023, 6:41 am

biomea fusion stock soars to record high

The shares of biomea Fusion Inc (NASDAQ:BMEA) are soaring today, up 88.1% at $29.03 at last glance and ...

March 28, 2023, 3:00 pm


Search within

Pages Search Results: